In a follow-up video to her immediate impressions from SABCS 2024, Avan J. Armaghani, MD, provides more specific clinical context for data from various breast cancer studies. The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer, with promising results, especially when combined with abemaciclib, showing progression-free survival regardless of ESR1 mutation status. Dr Armaghani emphasizes that oral SERDs appear to outperform fulvestrant, raising questions about sequencing and whether mutation status is necessary for treatment.
The OlympiA study reinforced the benefit of adjuvant PARP inhibitors for BRCA1/2 mutation carriers, highlighting the importance of genetic testing in identifying patients who would benefit from this therapy. Lastly, the HER3-DXd antibody-drug conjugate study presented a potential new therapy for patients with high-risk hormone receptor–positive, HER2-negative breast cancer in the neoadjuvant setting, encouraging further exploration of novel treatment strategies for this population.
Medscape © 2025 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.
Comments